Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
161.1
USD
|
-4.45%
|
|
-0.69%
|
-10.66%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
10,134
|
23,494
|
27,843
|
22,843
|
18,862
|
16,851
|
-
|
-
|
Enterprise Value (EV)
1 |
9,392
|
19,361
|
24,097
|
19,511
|
16,564
|
15,265
|
15,830
|
15,447
|
P/E ratio
|
-10.5
x
|
-13.5
x
|
-17.8
x
|
-11.3
x
|
-21.3
x
|
-17.4
x
|
-44.8
x
|
43.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
23.7
x
|
76.1
x
|
23.7
x
|
16.1
x
|
7.67
x
|
5.29
x
|
4.22
x
|
3.38
x
|
EV / Revenue
|
21.9
x
|
62.7
x
|
20.5
x
|
13.8
x
|
6.74
x
|
4.79
x
|
3.96
x
|
3.1
x
|
EV / EBITDA
|
-9.98
x
|
-11.9
x
|
-17.3
x
|
-11.3
x
|
-14.8
x
|
-19
x
|
-43.5
x
|
34.8
x
|
EV / FCF
|
-11.2
x
|
-13.8
x
|
-15.4
x
|
-10.7
x
|
-9.63
x
|
-41.9
x
|
-40.1
x
|
30.1
x
|
FCF Yield
|
-8.94%
|
-7.24%
|
-6.48%
|
-9.34%
|
-10.4%
|
-2.38%
|
-2.5%
|
3.32%
|
Price to Book
|
11.2
x
|
5.57
x
|
4.03
x
|
5.17
x
|
5.32
x
|
5.98
x
|
6.36
x
|
5.02
x
|
Nbr of stocks (in thousands)
|
61,136
|
90,924
|
102,770
|
103,859
|
104,578
|
104,579
|
-
|
-
|
Reference price
2 |
165.8
|
258.4
|
270.9
|
219.9
|
180.4
|
161.1
|
161.1
|
161.1
|
Announcement Date
|
3/2/20
|
2/25/21
|
2/25/22
|
2/27/23
|
2/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
428.2
|
308.9
|
1,176
|
1,416
|
2,459
|
3,188
|
3,993
|
4,978
|
EBITDA
1 |
-941.3
|
-1,626
|
-1,392
|
-1,723
|
-1,120
|
-803.7
|
-364.1
|
444
|
EBIT
1 |
-959.9
|
-1,658
|
-1,439
|
-1,790
|
-1,208
|
-988
|
-448.1
|
386.2
|
Operating Margin
|
-224.16%
|
-536.69%
|
-122.31%
|
-126.4%
|
-49.12%
|
-30.99%
|
-11.22%
|
7.76%
|
Earnings before Tax (EBT)
1 |
-943.6
|
-1,618
|
-1,439
|
-1,961
|
-825.8
|
-939.4
|
-363.9
|
433.4
|
Net income
1 |
-948.6
|
-1,597
|
-1,413
|
-2,004
|
-881.7
|
-950.2
|
-317
|
325.8
|
Net margin
|
-221.53%
|
-517.01%
|
-120.15%
|
-141.52%
|
-35.86%
|
-29.81%
|
-7.94%
|
6.54%
|
EPS
2 |
-15.80
|
-19.13
|
-15.23
|
-19.43
|
-8.450
|
-9.245
|
-3.595
|
3.693
|
Free Cash Flow
1 |
-839.9
|
-1,401
|
-1,562
|
-1,822
|
-1,719
|
-364
|
-395
|
512.5
|
FCF margin
|
-196.14%
|
-453.57%
|
-132.76%
|
-128.68%
|
-69.93%
|
-11.42%
|
-9.89%
|
10.29%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
115.43%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
157.28%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/20
|
2/25/21
|
2/25/22
|
2/27/23
|
2/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2021 S2
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
214
|
420.4
|
306.6
|
341.6
|
387.6
|
380.1
|
606.4
|
447.8
|
595.3
|
1,043
|
781.3
|
634.4
|
751.7
|
778.5
|
853.4
|
852.9
|
798
|
961.6
|
EBITDA
1 |
-558.6
|
-
|
-426.7
|
-423.9
|
-422.2
|
-450.6
|
-
|
-351.2
|
-
|
-
|
-112.5
|
-565.3
|
-236.1
|
-225.9
|
-222.4
|
-214.2
|
-115.2
|
-85.78
|
EBIT
1 |
-571.7
|
-
|
-443.3
|
-439.4
|
-438.4
|
-468.6
|
-907
|
-371.3
|
-318.7
|
-690
|
-134
|
-589.1
|
-261.3
|
-248.6
|
-237.6
|
-240.7
|
-169.9
|
-116.6
|
Operating Margin
|
-267.19%
|
-
|
-144.57%
|
-128.64%
|
-113.09%
|
-123.29%
|
-149.56%
|
-82.91%
|
-53.54%
|
-66.15%
|
-17.15%
|
-92.86%
|
-34.77%
|
-31.94%
|
-27.85%
|
-28.22%
|
-21.29%
|
-12.12%
|
Earnings before Tax (EBT)
1 |
-586.8
|
-
|
-421.2
|
-557.6
|
-551.2
|
-431
|
-982.2
|
-336.9
|
-367.5
|
-704.4
|
229.3
|
-350.8
|
-243.4
|
-258.7
|
-237.6
|
-212.3
|
-185.1
|
-107.9
|
Net income
1 |
-585.7
|
-999.5
|
-434.3
|
-571.4
|
-557.6
|
-445.3
|
-998.1
|
-348.4
|
-381.1
|
-729.6
|
215.4
|
-367.6
|
-251.2
|
-255.8
|
-234.8
|
-222.1
|
-185.1
|
-107.9
|
Net margin
|
-273.7%
|
-237.74%
|
-141.63%
|
-167.3%
|
-143.84%
|
-117.16%
|
-164.59%
|
-77.81%
|
-64.03%
|
-69.94%
|
27.57%
|
-57.94%
|
-33.41%
|
-32.85%
|
-27.52%
|
-26.04%
|
-23.2%
|
-11.22%
|
EPS
2 |
-6.160
|
-
|
-4.240
|
-5.560
|
-5.390
|
-4.290
|
-
|
-3.340
|
-3.640
|
-
|
2.010
|
-3.480
|
-2.410
|
-2.453
|
-2.248
|
-2.121
|
-1.810
|
-1.050
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/22
|
2/25/22
|
5/5/22
|
8/4/22
|
11/9/22
|
2/27/23
|
2/27/23
|
5/4/23
|
8/2/23
|
8/2/23
|
11/9/23
|
2/26/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
742
|
4,132
|
3,746
|
3,332
|
2,297
|
1,586
|
1,021
|
1,404
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-840
|
-1,401
|
-1,562
|
-1,822
|
-1,719
|
-364
|
-395
|
512
|
ROE (net income / shareholders' equity)
|
-70.2%
|
-66.1%
|
-28%
|
-38.1%
|
-22.3%
|
-28.7%
|
-10.9%
|
12.6%
|
ROA (Net income/ Total Assets)
|
-49.1%
|
-44.3%
|
-19.8%
|
-26.9%
|
-14.5%
|
-17.3%
|
-7.15%
|
6.12%
|
Assets
1 |
1,931
|
3,607
|
7,123
|
7,457
|
6,093
|
5,497
|
4,434
|
5,323
|
Book Value Per Share
2 |
14.80
|
46.40
|
67.30
|
42.50
|
33.90
|
27.00
|
25.30
|
32.10
|
Cash Flow per Share
2 |
-12.50
|
-15.40
|
-14.00
|
-14.50
|
-11.10
|
-1.800
|
-0.6100
|
5.300
|
Capex
1 |
89.6
|
118
|
263
|
325
|
562
|
256
|
247
|
274
|
Capex / Sales
|
20.93%
|
38.04%
|
22.35%
|
22.98%
|
22.85%
|
8.02%
|
6.19%
|
5.5%
|
Announcement Date
|
3/2/20
|
2/25/21
|
2/25/22
|
2/27/23
|
2/26/24
|
-
|
-
|
-
|
Last Close Price
161.1
USD Average target price
266.7
USD Spread / Average Target +65.49% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.66% | 16.85B | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | +3.75% | 13.76B | | +36.70% | 12.46B | | +295.70% | 8.12B |
Bio Therapeutic Drugs
|